Targeting synaptic pathology with a novel affinity mass spectrometry approach.
about
The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular eventsSynaptic Interactome Mining Reveals p140Cap as a New Hub for PSD Proteins Involved in Psychiatric and Neurological Disorders.Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry.Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability.Proteomics applications in prion biology and structure.Proteomics in the Diagnosis of Inborn Encephalopathies of Unknown Origin: A Myth or Reality.
P2860
Targeting synaptic pathology with a novel affinity mass spectrometry approach.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Targeting synaptic pathology with a novel affinity mass spectrometry approach.
@en
Targeting synaptic pathology with a novel affinity mass spectrometry approach.
@nl
type
label
Targeting synaptic pathology with a novel affinity mass spectrometry approach.
@en
Targeting synaptic pathology with a novel affinity mass spectrometry approach.
@nl
prefLabel
Targeting synaptic pathology with a novel affinity mass spectrometry approach.
@en
Targeting synaptic pathology with a novel affinity mass spectrometry approach.
@nl
P2093
P2860
P50
P356
P1476
Targeting synaptic pathology with a novel affinity mass spectrometry approach.
@en
P2093
Annika Öhrfelt
Giovanna R Mallucci
Joel Jakobsson
Julie A Moreno
William G Honer
P2860
P304
P356
10.1074/MCP.M114.040113
P577
2014-06-27T00:00:00Z